| In millions, except per share items | Dec-31-17 | Dec-31-16 | Mar-31-15 | Mar-31-14 | Mar-31-13 | Mar-31-12 | Mar-31-11 | Mar-31-10 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Urology | 49.3 | 44.7 | | | | | | |
| Industrial | 3.7 | 3.9 | | | | | 2.5 | 2.9 |
| Airway Management | 3.3 | 3.2 | | | | | | |
| United States | | | | | | | 7.3 | 7.9 |
| Other | | | | | | | 1.1 | 0.0 |
| Total revenues | 56.3 | 51.9 | 26.5 | 24.6 | 22.4 | 16.7 | 10.9 | 10.8 |
| Revenue growth [+] | 8.6% | | 7.9% | 9.6% | 34.4% | 53.1% | 0.8% | -15.8% |
| Urology | 10.2% | | | | | | | |
| Industrial | -4.4% | | | | | | -13.0% | 3.3% |
| Airway Management | 2.2% | | | | | | | |
| United States | | | | | | | -7.5% | -24.0% |
| Europe | | | | | | | 25.4% | 47.8% |
| Cost of goods sold | 18.9 | 16.2 | 3.1 | 3.0 | 3.0 | 11.6 | 8.0 | 9.8 |
| Gross profit | 37.4 | 35.6 | 23.4 | 21.5 | 19.4 | 5.1 | 2.9 | 1.0 |
| Gross margin | 66.5% | 68.7% | 88.2% | 87.6% | 86.6% | 30.5% | 26.8% | 9.4% |
| Selling, general and administrative [+] | 31.2 | 28.1 | 28.2 | 24.6 | 19.4 | 12.0 | 10.8 | 10.5 |
| Sales and marketing | 22.9 | 21.3 | 20.2 | 18.1 | 15.2 | | | |
| General and administrative | 8.3 | 6.8 | 8.0 | 6.5 | 4.2 | | | |
| Research and development | 4.7 | 4.7 | 2.9 | 2.2 | 2.4 | 3.2 | 3.5 | 3.3 |
| Equity in earnings | 0.1 | | | | | | | |
| Other operating expenses | 2.4 | 4.6 | 0.0 | 0.0 | 0.9 | | | |
| EBITDA [+] | 2.4 | 1.3 | -7.4 | -4.9 | -2.1 | -9.3 | -10.6 | -12.1 |
| EBITDA growth | 81.5% | | 49.0% | 130.2% | -76.9% | -12.5% | -12.4% | -1.9% |
| EBITDA margin | 4.3% | 2.6% | -27.8% | -20.1% | -9.6% | -55.6% | -97.4% | -112.0% |
| Depreciation and amortization | 0.8 | 0.8 | 0.2 | 0.3 | 0.3 | 0.8 | 0.7 | 0.7 |
| EBITA | 1.6 | 0.6 | -7.6 | -5.3 | -2.4 | -10.1 | -11.4 | -12.8 |
| EBITA margin | 2.9% | 1.1% | -28.7% | -21.4% | -10.9% | -60.6% | -104.2% | -118.1% |
| Amortization of intangibles | 2.4 | 2.4 | 0.0 | 0.0 | 0.9 | | | |
| EBIT [+] | -0.8 | -1.8 | -7.6 | -5.3 | -3.3 | -10.1 | -11.4 | -12.8 |
| EBIT growth | -58.0% | | 44.3% | 60.5% | -67.4% | -11.0% | -11.0% | -0.4% |
| EBIT margin | -1.4% | -3.5% | -28.8% | -21.6% | -14.7% | -60.6% | -104.2% | -118.1% |
| Interest expense, net [+] | 0.0 | 1.3 | 0.0 | 0.0 | 0.0 | 0.5 | 0.3 | 0.0 |
| Interest expense | 0.0 | 1.3 | 0.0 | | 0.0 | 0.5 | 0.3 | 0.0 |
| Interest income | | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | 0.2 | -18.8 | 0.0 | 0.0 | 0.0 | -0.4 | -0.1 | 0.0 |
| Gain (loss) on foreign currency transactions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | |
| Other | 0.0 | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Pre-tax income | -0.6 | -22.0 | -7.6 | -5.3 | -3.3 | -11.0 | -11.8 | -12.8 |
| Income taxes | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | -0.4 |
| Tax rate | | | | | | | | 3.0% |
| Net income | -0.9 | -22.1 | -7.7 | -5.4 | -3.3 | -11.0 | -11.8 | -12.4 |
| Net margin | -1.6% | -42.6% | -29.1% | -21.8% | -14.7% | -66.0% | -108.7% | -114.9% |
| |
| Basic EPS [+] | ($0.01) | ($0.71) | ($0.49) | ($0.35) | ($0.22) | ($0.25) | ($0.31) | ($0.34) |
| Growth | -97.9% | | 40.3% | 59.3% | -12.1% | -19.4% | -8.3% | 69.7% |
| Diluted EPS [+] | ($0.01) | ($0.71) | ($0.49) | ($0.35) | ($0.22) | ($0.25) | ($0.31) | ($0.34) |
| Growth | -97.9% | | 40.3% | 59.3% | -12.1% | -19.4% | -8.3% | 69.7% |
| |
| Shares outstanding (basic) [+] | 60.0 | 30.9 | 15.8 | 15.3 | 15.1 | 44.2 | 38.3 | 36.9 |
| Growth | 94.1% | | 2.7% | 1.6% | -65.9% | 15.5% | 4.0% | -1.4% |
| Shares outstanding (diluted) [+] | 60.0 | 30.9 | 15.8 | 15.3 | 15.1 | 44.2 | 38.3 | 36.9 |
| Growth | 94.1% | | 2.7% | 1.6% | -65.9% | 15.5% | 4.0% | -1.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |